ClinicalTrials.gg
RecruitingNCT07112014GastroRehabUpdated Sep 23, 2025

Development of Gastrointestinal Symptoms in Patients With Anorexia Nervosa and Bulimia Nervosa During Weight Rehabilitation Over Time, Depending on the Nutritional Strategy

An observational study in Anorexia Nervosa and Bulimia Nervosa, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
185
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Anorexia Nervosa with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Anorexia Nervosa · Germany.

Started
2025
with 2 others
Observational
9 of 14
3 open now
Registered
13th of 14
by date
Lead sponsor
1 of 14
University Hospital Tuebingen

Among the 14 studies in Anorexia Nervosa with a site in Germany, this one is one of 3 that started in 2025, is one of 9 observational ones, and was the 13th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

4 of the 14 studies in Anorexia Nervosa with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Anorexia Nervosa with a site in Germany, or all of them as a file.
02

Study summary

This prospective observational study investigates the development of gastrointestinal (GI) symptoms in patients with anorexia nervosa (AN) and bulimia nervosa (BN) during multi-week inpatient weight rehabilitation. The study explores how the predominant nutritional strategy-flexitarian, vegetarian, or vegan-relates to changes in GI symptoms over the course of treatment. In addition to diet, the study examines how weight gain and other clinical, psychological, and demographic factors influence the trajectory of GI symptoms. Patients complete weekly questionnaires assessing GI symptoms as part of routine care at the Eating Disorder Center of the Klinik Lüneburger Heide, Germany. Further data are drawn from standard clinical assessments, including body weight, body composition, and psychometric instruments. The primary outcome is the change in GI symptom severity (measured via the GSRS score) from admission to discharge, analyzed in relation to dietary pattern and weight development. Secondary analyses will explore symptom progression over time, group differences between AN and BN, and predictors of GI symptom improvement, including dietary intake, baseline psychological status, symptom change, weight trajectory, and treatment duration. The outcomes will be analyzed separately for AN and BN. The study aims to recruit approximately 150 patients with AN and 35-40 with BN. Inclusion requires a diagnosis of AN (any subtype) or BN, age over 12 years, clinical stability, and the ability to provide informed consent. The findings aim to inform evidence-based dietary recommendations for individuals with eating disorders who experience significant GI symptoms during nutritional rehabilitation.

Read the detailed description

This prospective observational study investigates the development of gastrointestinal (GI) symptoms in patients with anorexia nervosa (AN) and bulimia nervosa (BN) during multi-week inpatient weight rehabilitation. The study explores how the predominant nutritional strategy-flexitarian, vegetarian, or vegan-relates to changes in GI symptoms over the course of treatment. In addition to diet, the study examines how weight gain and other clinical, psychological, and demographic factors influence the trajectory of GI symptoms. Patients complete weekly questionnaires assessing GI symptoms as part of routine care at the Eating Disorder Center of the Klinik Lüneburger Heide, Germany. Further data are drawn from standard clinical assessments, including body weight, body composition, and psychometric instruments. The primary outcome is the change in GI symptom severity (measured via the GSRS score) from admission to discharge, analyzed in relation to dietary pattern and weight development. Secondary analyses will explore symptom progression over time, group differences between AN and BN, and predictors of GI symptom improvement, including dietary intake, baseline psychological status, symptom change, weight trajectory, and treatment duration. The study aims to recruit approximately 150 patients with AN and 35-40 with BN. Inclusion requires a diagnosis of AN (any subtype) or BN, age over 12 years, clinical stability, and the ability to provide informed consent. The findings aim to inform evidence-based dietary recommendations for individuals with eating disorders who experience significant GI symptoms during nutritional rehabilitation.

03

Conditions studied

  • Anorexia Nervosa
  • Bulimia Nervosa

Keywords

  • gastrointestinal symptoms
  • gastrointestinal health
  • dietary regime
  • psychological health
  • vegetarian diet
  • vegan diet
  • balanced diet
  • energy intake
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Anorexia nervosa and Bulimia nervosa. All subtypes will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients diagnosed with anorexia nervosa (all subtypes)
  • patients diagnosed bulimia nervosa

Exclusion criteria

Exclusion Criteria:

  • patients that are medically unable to fill out a short questionnaire on a weekly base.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
185 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with anorexia nervosa and bulimia nervosa

    The study population includes patients with anorexia nervosa (AN) and bulimia nervosa (BN) who participate in an established, multi-week inpatient treatment program aimed at weight rehabilitation and normalization of eating behavior at the Eating Disorder Center of the Klinik Lüneburger Heide in 29549 Bad Bevensen, Germany. The diagnostic and treatment of the patients is as usual. These data, including detailed data on dietary intake, are used for the study. Additionally, information on gastrointestinal sympoms are assessed upon admission and discharge and weekly during the inpatient stay. The outcomes will be analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal Symptoms

    Score of the Gastrointestinal Symptom Rating Scale assessed upon admission and discharge (two time points), in relation to the predominant dietary pattern (\>80% during the rehabilitation phase), defined as flexitarian, vegetarian, or vegan and body weight development. The Gastrointestinal Symptom Rating Scale is a validated questionnaire : Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. (1988) 33(2):129-34. doi: 10.1007/BF01535722. The primary outcome is analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

Secondary outcomes

  1. Gastrointestinal Symptoms in the Timecourse

    The Gastrointestinal Symptom Rating Scale is assessed weekly during inpatient treament.

    Time frame: Data are continuously collected from admission to discharge. Extraction occurs on the first three days of admission, weekly during the stay (on Mondays or Tuesdays, covering the preceding week), and on the final three days of discharge.

  2. Dietary intake

    Dietary intake is closely monitored from the beginning to the end of the inpatients stay. The data of the plans will be summarized weekly, containing information on the intake of macro- and micronutrients, fibre, energy intake and food groups. The outcome is analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are continuously collected throughout the inpatient stay. Extraction takes place on the day of admission, weekly during the stay (on Mondays or Tuesdays, reflecting the data of the preceding week), and on the day of discharge.

  3. Body weight

    Body weight in kg is measured in underwear in the morning before breakfast using a calibrated scale in order to calculate the Body mass index or body mass index z-score. The outcome is analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are continuously collected from admission to discharge. Extraction occurs the second day in the morning after admission, weekly during the stay (on Mondays or Tuesdays), and at the day of discharge

  4. Body height

    Body height in cm is measured using a standardized stadiometer to calculate the body mass index or the body mass index z-score. The outcome is analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Body weight is measured within the first two days after admission and again within the final two days prior to discharge. For inpatient stays exceeding three months, weight measurements are repeated at three-month intervals.

  5. Body composition

    Body composition is measured with bioelectrical impedance

    Time frame: Body composition is measured within the first two days after admission and again within the final two days prior to discharge. The outcome is analyzed seperately for patients with anorexia nervosa and bulimia nervosa.

  6. Eating Disorder Inventory-2 (EDI-2)

    Eating Disorder Inventory-2 (EDI-2): A 91-item self-report questionnaire assessing psychological and behavioral traits related to eating disorders across 11 subscales. Each item is scored from 0 to 2; total scores range from 0 to 182, with higher scores indicating worse outcomes (greater symptom severity. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  7. Three Factor Eating Questionnaire (TFEQ)

    This is a self-report measure of eating behavior with 51 items across three subscales: Cognitive Restraint, Disinhibition, and Hunger. Items are primarily dichotomous (yes/no), with some Likert-scale items. Subscale scores vary in range, and the total score ranges from 0 to 51, with higher scores indicating worse outcomes (e.g., more disinhibited eating, greater hunger, or excessive restraint). Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  8. Symptom-Checkliste (SCL-90-R)

    Symptom-Checklist-90-Revised (SCL-90-R): A 90-item self-report questionnaire assessing general psychological distress across 9 symptom dimensions (e.g., depression, anxiety, somatization) and 3 global indices. Each item is rated from 0 (not at all) to 4 (extremely). Total scores range from 0 to 360, with higher scores indicating worse psychological symptom severity. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  9. Beck-Depressions-Inventar Revision (BDI-II)

    This is a 21-item self-report questionnaire assessing the severity of depressive symptoms over the past two weeks. Each item is rated on a scale from 0 to 3. Total scores range from 0 to 63, with higher scores indicating worse depressive symptom severity. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  10. Obsessive Compulsive Inventory - Revised (OCI-R)

    This is an 18-item self-report questionnaire measuring the severity of obsessive-compulsive symptoms across 6 subscales (e.g., washing, checking, hoarding). Each item is rated from 0 (not at all) to 4 (extremely). Total scores range from 0 to 72, with higher scores indicating worse obsessive-compulsive symptom severity. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  11. Generalizied Anxiety Disorder Scale-7 (GAD-7)

    This is a 7-item self-report questionnaire assessing symptoms of generalized anxiety over the past two weeks. Each item is rated from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 21, with higher scores indicating worse anxiety symptom severity. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  12. Wender Utah Rating Scale (WURS-K)

    This is a 25-item self-report questionnaire assessing retrospective childhood symptoms of ADHD in adults. Each item is rated from 0 (not at all or never) to 4 (very much or very often). Total scores range from 0 to 100, with higher scores indicating greater severity of ADHD-related childhood symptoms. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  13. Subthreshold Autism Trait Questionnaire (SATQ)

    This is a 24-item self-report questionnaire measuring the presence of subclinical autistic traits in adults. Each item is rated from 0 (strongly disagree) to 3 (strongly agree). Total scores range from 0 to 72, with higher scores indicating more pronounced subthreshold autistic traits.Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  14. Frost Multidi-mensional Perfectionism Scale (FMPS)

    This is a 35-item self-report questionnaire assessing perfectionism across multiple dimensions, including concern over mistakes, personal standards, and parental expectations. Each item is rated from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 35 to 175, with higher scores indicating greater levels of perfectionism. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  15. Perceived Stress Questionnaire (PSQ)

    This is a self-report instrument assessing subjective experiences of stress over the past weeks. The standard version includes 30 items, each rated on a scale from 1 (almost never) to 4 (usually). Total scores range from 30 to 120, with higher scores indicating greater perceived stress. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data are collected within the first three days after admission and during the final three days before discharge (two time points).

  16. Age

    Age is assessed by documenting the birth date (day, months, year) from the health insurance card.

    Time frame: This is assessed upon admission.

  17. Complete Blood Count (CBC) with Differential

    Complete Blood Count (CBC) with Differential: A standard laboratory test used to assess general health and detect hematological abnormalities. Measures include red blood cells, white blood cells, hemoglobin, hematocrit, platelets, and a differential count of white blood cell subtypes (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Results outside reference ranges may indicate infection, anemia, inflammation, or immune response abnormalities. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data will be analyzed from samples collected within the first 3 days after hospital admission, weekly throughout the inpatient stay (on or around Day 7, Day 14, etc.), and within the final 3 days prior to discharge.

  18. Key electrolyte panel for fluid balance, neuromuscular function, and metabolic regulation

    A standard blood chemistry panel measuring key electrolytes involved in fluid balance, neuromuscular function, and metabolic regulation. Sodium (Na⁺): typically 135-145 mmol/L Potassium (K⁺): typically 3.5-5.0 mmol/L Chloride (Cl-): typically 98-107 mmol/L Magnesium (Mg²⁺): typically 0.7-1.0 mmol/L Phosphate (PO₄³-): typically 0.8-1.5 mmol/L Abnormal values may indicate renal dysfunction, metabolic imbalance, or effects of medications. Higher or lower levels indicate worse physiological regulation depending on the parameter. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data will be analyzed from samples collected within the first 3 days after hospital admission, weekly throughout the inpatient stay (on or around Day 7, Day 14, etc.), and within the final 3 days prior to discharge.

  19. Liver Function Panel

    This Liver Function Panel (ALT, AST, GGT, ALP, Bilirubin, Albumin, INR) is a comprehensive blood test panel assessing hepatocellular injury and liver synthetic function. Alanine aminotransferase (ALT): \< 50 U/L Aspartate aminotransferase (AST): \< 50 U/L Gamma-glutamyl transferase (GGT): \< 60 U/L Alkaline phosphatase (ALP): 35-125 U/L Total Bilirubin: 0.3-1.2 mg/dL Albumin: 3.5-5.0 g/dL International Normalized Ratio (INR): 0.9-1.2 Elevated enzyme levels may indicate hepatocellular injury or cholestasis, while changes in bilirubin, albumin, or INR reflect impaired liver function. Deviations from normal values indicate worsening liver status, depending on the parameter. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data will be analyzed from samples collected within the first 3 days after hospital admission, weekly throughout the inpatient stay (on or around Day 7, Day 14, etc.), and within the final 3 days prior to discharge.

  20. Renal Function Panel

    This Renal Function Panel (Creatinine, Urea/BUN, eGFR) is a standard blood test panel assessing kidney function and glomerular filtration. Serum Creatinine: typically 0.6-1.3 mg/dL Blood Urea Nitrogen (BUN)/Urea: typically 7-20 mg/dL (or 2.5-7.1 mmol/L) Estimated Glomerular Filtration Rate (eGFR): \> 90 mL/min/1.73 m² (normal) Abnormal values may indicate impaired renal function, dehydration, or nephrotoxic effects. Higher creatinine or BUN and lower eGFR indicate worse kidney function. Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data will be analyzed from samples collected within the first 3 days after hospital admission, weekly throughout the inpatient stay (on or around Day 7, Day 14, etc.), and within the final 3 days prior to discharge.

  21. Medication Use

    Self-reported and/or medically verified use of prescribed or over-the-counter medications during the study period, with a focus on agents affecting gastrointestinal physiology. Values are recorded categorically (e.g., no medication, antidepressants, antipsychotics, anxiolytics, GI-active drugs, other). Data are analyzed separately for patients with anorexia nervosa and bulimia nervosa.

    Time frame: Data will be analyzed from samples collected within the first 3 days after hospital admission, weekly throughout the inpatient stay (on or around Day 7, Day 14, etc.), and within the final 3 days prior to discharge.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ketel J, Bosch-Bruguera M, Auchter G, Cuntz U, Zipfel S, Enck P, Mack I. Gastrointestinal Microbiota & Symptoms of Depression and Anxiety in Anorexia Nervosa-A Re-Analysis of the MICROBIAN Longitudinal Study. Nutrients. 2024 Mar 19;16(6):891. doi: 10.3390/nu16060891. PubMed 38542802 ↗
  • Mack I, Cuntz U, Gramer C, Niedermaier S, Pohl C, Schwiertz A, Zimmermann K, Zipfel S, Enck P, Penders J. Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints. Sci Rep. 2016 May 27;6:26752. doi: 10.1038/srep26752. PubMed 27229737 ↗
  • Riedlinger C, Schmidt G, Weiland A, Stengel A, Giel KE, Zipfel S, Enck P, Mack I. Which Symptoms, Complaints and Complications of the Gastrointestinal Tract Occur in Patients With Eating Disorders? A Systematic Review and Quantitative Analysis. Front Psychiatry. 2020 Apr 20;11:195. doi: 10.3389/fpsyt.2020.00195. eCollection 2020. PubMed 32425816 ↗
  • Riedlinger C, Mazurak N, Schaffeler N, Stengel A, Giel KE, Zipfel S, Enck P, Mack I. Gastrointestinal complaints in patients with anorexia nervosa in the timecourse of inpatient treatment. Front Psychiatry. 2022 Aug 18;13:962837. doi: 10.3389/fpsyt.2022.962837. eCollection 2022. PubMed 36061281 ↗

Individual participant data

Plan to share: No — Patient data. Potential collaborators should contact us directly.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 22 months is below that.

Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Aug 8, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07112014
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Sep 9, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

Isabelle Mack, Prof. Dr.
Contact
i.mack@uni-tuebingen.de
+49 070712985614
Marc Leiteritz, Dr.
Contact
m.leiteritz@klinik-lueneburger-heide.de
Isabelle Mack, Prof.
principal investigator · University Hospital Tuebingen, Internal Medicine VI, Dept. of Psychosomatic Medicine and Psychotherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion